Sharemaestro company-news research for AstraZeneca PLC (AZN), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.
BUE
Argentina
Measured evidence
Company news sentiment
AZN news sentiment
AstraZeneca PLC
Company headlines from the last 30 days, weighted by freshness, relevance, publisher quality and the strength of the wording. Price is shown separately.
30-day score56Neutral is 50
Balanced news tone
40/100 evidence confidence
97% direct company focus
13 current stories across 5 publishers
Current company news
Balanced news tone
The score uses 13 current company stories from 5 publishers.
Observed headline tone62/100
→
Published 30-day score56/100
Latest source headline
How AstraZeneca’s $400bn deal unravelled
finance.yahoo.com · 12 Aug 2026 04:00
Older, less relevant and less reliable stories count for less. Confidence is shown separately.
What supports the score
13 current stories are mapped specifically to AZN.
The score uses 5 publishers rather than depending on one outlet.
The current stories agree at 86/100.
What limits the score
Price is moving more forcefully than the current news tone suggests.
56/100
News scoreBalanced news tone
40/100
Confidencebuilding confidence
97%/100
Company news13 company stories
86/100
Story agreement14/100 difference
News history
Daily score and story count over 30 days
15 Jul30 Jul13 Aug
News scoreStory count50 baseline
Confidence
How reliable the score is
Confidence uses the amount of news, separate publishers, direct company relevance, freshness and agreement. A high or low score is not automatically reliable.
Amount of evidence20
0.984 after freshness weightingSource breadth100
5 independent publishersCompany relevance97
share tied directly to this companyFreshness60
recency-weighted evidenceAgreement86
how closely stories agreePublisher mix49
less reliance on one publisherPrice and news history
News score and weekly price over 26 weeks
Price is moving more forcefully than the current news tone suggests.
One scoring method across the chart.Stored company headlines are recalculated at each weekly point with the current 30-day freshness weighting. Old published snapshots are left unchanged.
13 Feb15 May07 Aug
Weekly close, indexedSentiment score
WeekNews scoreCloseWeekly move
07 Aug 202650ARS 63825.0-4.1%
31 Jul 202648ARS 66555.67-0.8%
24 Jul 202647ARS 67102.23+1.6%
17 Jul 202647ARS 66058.8-1.3%
10 Jul 202646ARS 66903.48-15.8%
03 Jul 202650ARS 79499.12+9.5%
26 Jun 202650ARS 72625.0+10.2%
19 Jun 202651ARS 65900.0-1.5%
News subjects
What is shaping the score
Deals and strategy454 stories · 31%
Earnings703 stories · 23%
Analyst action742 stories · 15%
Market update572 stories · 15%
Guidance562 stories · 15%
Source mix
Where the evidence comes from
finance.yahoo.com657 stories · 54%
Traders Union562 stories · 15%
seekingalpha.com502 stories · 15%
DirectorsTalk Interviews631 stories · 8%
ITVX501 stories · 8%
Recurring subjects
Subjects appearing most often
Pharma4Earnings4Oncology3M A3Biotech3Price Target2Fda Approval2Earnings Per Share2Trials1Split1
Earlier readings
How the score has changed
Past and present use the same method.Each point recalculates the previous 30 days of stored company headlines with today's scoring rules. The original stored snapshots remain unchanged.
18 Jun50 neutral13 Aug 23:50
ConstructiveBalanced or withheldCautious
Changes in the stored score
Scores are rebuilt from stored headlines with the current 30-day method. Days with no change are collapsed.
| Observed | Score | Move | Confidence | Stories | Status |
|---|---|---|---|---|---|
| 13 Aug 23:50 | 58 | -1 | 45/100 (-4) | 38 (-1) | Measured |
| 12 Aug 23:59 | 59 | +0 | 49/100 (-2) | 39 (0) | Measured |
| 11 Aug 23:59 | 59 | +1 | 51/100 (+8) | 39 (+7) | Measured |
| 10 Aug 23:59 | 58 | +3 | 43/100 (+3) | 32 (+3) | Measured |
| 09 Aug 23:59 | 55 | +5 | 40/100 (+3) | 29 (+1) | Measured |
| 08 Aug 23:59 | 50 | +0 | 37/100 (+3) | 28 (+2) | Measured |
| 07 Aug 23:59 | 50 | +1 | 34/100 (+3) | 26 (0) | Provisional |
| 05 Aug 23:59 | 49 | +0 | 31/100 (-1) | 26 (-1) | Provisional |
Source headlines
The news behind the score
Only company-specific stories enter this score. The latest 30 days are shown newest first, with newer stories weighted more heavily and duplicate coverage combined.
#176Tone
finance.yahoo.comDirect company coverageStored article
How AstraZeneca’s $400bn deal unravelled
One Broadway deal to start: Hollywood mogul Ari Emanuel has struck a roughly £4.5bn deal to buy the theatre group behind West End venues including the Lyceum and the Savoy in a major bet that strong demand for live events is here to stay. In today's newsletter: AstraZeneca's Silver Upgrade to read this Financial Times article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade now
- Published
- 12 Aug 2026 04:00
- News subject
- Analyst action
- Why this score
- Operating growth
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Medium · 12.9% · 1.8d old
- Duplicates
- 1 consolidated
#240Tone
finance.yahoo.comDirect company coverageStored article
AstraZeneca PLC (AZN) vs. Bristol-Myers Squibb Company (BMY): Wall Street Doesn’t Buy This Merger Talk
AstraZeneca PLC (NYSE:AZN) shares closed down as much as 9% on Monday, the stock's biggest one-day drop since 2020, after reports that it held merger talks with U.S. rival Bristol-Myers Squibb Company (NYSE:BMY). A combined company would be worth close to $400 billion, the fourth-largest drugmaker in the world by market value. Neither firm confirmed the talks, and people familiar with the matter told Reuters a deal may never materialize. Why Investors Can't Figure Out the Logic Bristol Myers shares actually rose as much as 6% on the news before dropping back down a bit, a very different reacti
M AOncologyPatent ExpiryPharmaSplit
- Published
- 11 Aug 2026 19:34
- News subject
- Deals and strategy
- Why this score
- Negative market reaction
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Medium · 11.6% · 2.2d old
- Duplicates
- 1 consolidated
#350Tone
finance.yahoo.comDirect company coverageStored article
Do Options Traders Know Something About AstraZeneca Stock We Don't?
Investors in AstraZeneca PLC AZN need to pay close attention to the stock based on moves in the options market lately. That is because the Jan. 15, 2027 $115.00 Call had some of the highest implied volatility of all equity options today. What is Implied Volatility? Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It could also mean there is an event coming up soon that may cause a big rally or a huge sell-off. Ho
BiotechImplied VolatilityOptions Trading
- Published
- 11 Aug 2026 14:11
- News subject
- Market update
- Why this score
- No clear positive or negative phrase
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Low · 2.5% · 2.4d old
- Duplicates
- 1 consolidated
#462Tone
finance.yahoo.comDirect company coverageStored article
Hedge Funds are Bullish on AstraZeneca PLC (AZN)
AstraZeneca PLC (NYSE:AZN) topped second-quarter profit expectations, with core earnings per share of $2.63 versus the $2.48 analysts expected. The firm reiterated its target of $80 billion in annual revenue by 2030. However, the quarter also brought fresh pipeline trouble: its rare disease drug Ultomiris missed its main goal in a late-stage trial for a rare blood vessel complication in adults, the latest in a string of setbacks that also includes an earlier heart drug trial failure and a breast cancer drug application that U.S. regulators rejected. Why One Trial Miss Shook Confidence in the W
EarningsEarnings Per ShareOncologyPharmaRegulationTrials
- Published
- 11 Aug 2026 14:04
- News subject
- Earnings
- Why this score
- Beat expectations
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Medium · 13.1% · 2.4d old
- Duplicates
- 1 consolidated
#550Tone
seekingalpha.comDirect company coverageStored article
Polen International Equity adds NOK, MUFG; exits AIVAF, RNMBF among Q2 moves
Polen International Equity Strategy outperformed the MSCI ACWI ex-US Index in the second quarter of 2026, returning 21.59% gross and 21.35% net of fees, respectively, versus 14.49% for the benchmark. During the quarter, the fund initiated new positions in ASPEED Technology, Ryohin Keikaku (RYKKF [https://seekingalpha.com/symbol/RYKKF]), Mitsubishi UFJ Financial Group (MUFG [https://seekingalpha.com/symbol/MUFG]), Tokio Marine Holdings (TKOMF [https://seekingalpha.com/symbol/TKOMF]), AstraZeneca (AZN [https://seekingalpha.com/symbol/AZN]), Nokia (NOK [https://seekingalpha.com/symbol/NOK]), Rent
EarningsFinancialsHealthcareRevenue Growth
- Published
- 11 Aug 2026 13:36
- News subject
- Earnings
- Why this score
- No clear positive or negative phrase
- Company focus
- Company discussed · 86%
- How it is used
- Direct company coverage
- Weighted influence
- Low · 5.9% · 2.4d old
- Duplicates
- 1 consolidated
#650Tone
finance.yahoo.comDirect company coverageStored article
A Profitable Rare-Disease Prize: Who Might Snap Up BioCryst?
Quick Read BioCryst hit its first full year of profitability in 2025, with Q2 2026 revenue up 34% to $218 million, fueling acquisition speculation. Takeda (TAK) tops the buyer rankings as navenibart directly threatens its Takhzyro franchise; AstraZeneca (AZN) ranks second through its Alexion rare-disease platform. Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and BioCryst Pharmaceuticals didn't make the cut. Grab the names FREE today. BioCryst Pharmaceuticals (NASDAQ:BCRX) closed at $9.84 on August 10, 2026, giving the Durham-based rare-disease specialist a m
BiotechEarningsFree Cash FlowGuidanceM AOperating Income
- Published
- 11 Aug 2026 13:20
- News subject
- Deals and strategy
- Why this score
- No clear positive or negative phrase
- Company focus
- Company discussed · 86%
- How it is used
- Direct company coverage
- Weighted influence
- Low · 5.4% · 2.4d old
- Duplicates
- 1 consolidated
#757Tone
Traders UnionDirect company coverageScored from headline
AstraZeneca stock outlook: Seller pressure limits upside for AZN
- Published
- 11 Aug 2026 08:02
- News subject
- Guidance
- Why this score
- Positive financial language
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Medium · 12.5% · 2.7d old
- Duplicates
- 1 consolidated
#881Tone
finance.yahoo.comDirect company coverageStored article
Can AstraZeneca (AZN) Reach Its $80 Billion Revenue Goal Despite Clinical Setbacks?
It was reported on July 27 that AstraZeneca PLC (NASDAQ:AZN) shares outperformed in European trading after the company reported second-quarter earnings that beat Wall Street expectations and reiterated its full-year 2026 guidance. Core earnings per share (EPS) jumped 18% on a constant exchange rate (FXN) basis year-over-year to $2.63, comfortably ahead of the $2.48 analyst consensus. Total revenue reached $15.38 billion, up 5% at constant exchange rates, driven primarily by sustained momentum in its Oncology and Rare Disease units. Management reconfirmed its full-year 2026 outlook of mid-to-hi
Balance SheetClinical TrialsDividendsEarningsEarnings GrowthEarnings Per Share
- Published
- 10 Aug 2026 23:44
- News subject
- Earnings
- Why this score
- Beat expectations, Positive market reaction
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- High · 20.1% · 3.0d old
- Duplicates
- 1 consolidated
#963Tone
DirectorsTalk InterviewsDirect company coverageScored from headline
AstraZeneca PLC (AZN) Stock Analysis: Unveiling a 32% Potential Upside Amid Strong Buy Ratings
- Published
- 10 Aug 2026 09:20
- News subject
- Market update
- Why this score
- Positive financial language
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Low · 3.1% · 3.6d old
- Duplicates
- 1 consolidated
#1050Tone
seekingalpha.comDirect company coverageStored article
SA Asks: What's the outlook for Big Pharma M&A?
[Medical research with pipette and test tube, DNA analysis, biotechnology, genetic science and healthcare] jittawit.21 Big Pharma moved back into the spotlight last week following a Financial Times report that Bristol Myers Squibb (BMY [https://seekingalpha.com/symbol/BMY]) was in merger talks with AstraZeneca (AZN [https://seekingalpha.com/symbol/AZN]), a development that was later denied by unnamed sources to Reuters. We asked Seeking Alpha analysts Stephen Ayers [https://seekingalpha.com/author/stephen-ayers], ALLKA Research [https://seekingalpha.com/author/allka-research], and Chris DeMuth
BiotechFda ApprovalM&aM AOncologyPharma
- Published
- 08 Aug 2026 19:28
- News subject
- Deals and strategy
- Why this score
- No clear positive or negative phrase
- Company focus
- Company discussed · 86%
- How it is used
- Direct company coverage
- Weighted influence
- Low · 4.5% · 5.2d old
- Duplicates
- 1 consolidated
#1167Tone
finance.yahoo.comDirect company coverageStored article
Roche Stock Jumps as Morgan Stanley Sees Drug Breakout
This article first appeared on GuruFocus. Roche Holding (RHHBY), the Swiss pharmaceutical and diagnostics giant, got a major Wall Street vote of confidence after Morgan Stanley upgraded the stock to Overweight from Equal Weight and hiked its ADR price target to $63 from $46. The upgrade helped send Roche's U.S.-traded ADRs up about 2.2% to $57.38 during Friday's session. Morgan Stanley also swapped out AstraZeneca as its top pharmaceutical pick in favor of Roche, a clear sign the bank believes the company's next growth story is gaining momentum. Warning! GuruFocus has detected 7 Warning Signs
Earnings EstimateFda ApprovalIntrinsic ValuePharmaPrice TargetPrice Target
- Published
- 07 Aug 2026 19:30
- News subject
- Analyst action
- Why this score
- Analyst upgrade, Positive market reaction
- Company focus
- Company discussed · 86%
- How it is used
- Direct company coverage
- Weighted influence
- Low · 3.9% · 6.2d old
- Duplicates
- 1 consolidated
#1250Tone
ITVXDirect company coverageScored from headline
Share price plummets as drugs giant AstraZeneca holds talks over possible merger | ITV News
- Published
- 03 Aug 2026 07:00
- News subject
- Deals and strategy
- Why this score
- No clear positive or negative phrase
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Low · 3% · 10.7d old
- Duplicates
- 1 consolidated
#1350Tone
Traders UnionDirect company coverageScored from headline
AstraZeneca stock forecast: Consolidation near GBX12,547 support
- Published
- 24 Jul 2026 07:00
- News subject
- Guidance
- Why this score
- No clear positive or negative phrase
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Low · 1.5% · 20.7d old
- Duplicates
- 1 consolidated
Earlier company news
AZN news archive
Stored newest first for historical research. It starts after the newest three pages above and then continues through older news. Each archive page is loaded only when it is opened.
Older news is kept in the archive
There are 53 older AZN headlines. Open one page at a time when you need them.
Open older archiveHow the page works
How to read the score
It describes the weighted balance of qualifying headlines. A score of 50 can mean balanced news or that there is not enough evidence; the status label explains which.
Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme.
Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.
It measures news already published. It is not a forecast, recommendation or price target.